Sun Pharmaceutical Industries (SUNPHARMA) investor relations material

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including innovative medicines, branded generics, generics, and APIs.

• Largest pharmaceutical company in India and 13th largest in the US generics market.

• 47,000+ employees and 40 manufacturing facilities globally, many approved by major regulators.

• Expanding presence in developed markets outside the US and strong focus on R&D and quality compliance.

Revenue composition and growth

• FY26 sales reached Rs 582 Bn, with India formulations contributing 33%, US 29%, Emerging Markets 19%, ROW 15%, and API & Others 4%.

• Sales grew at a 17% CAGR from FY11 to FY26, with EBITDA and net profit also showing double-digit CAGR.

• Gross margin improved to 80.2% in FY26, with EBITDA margin at 30.3%.

• Market capitalization stood at US $48 Bn as of September 2026.

Segment performance

• US business accounted for 29% of FY26 revenues, with a robust pipeline and 13th largest generics presence.

• India business led with 8.5% market share, No.1 by prescriptions in 12 doctor categories, and strong brand equity.

• Emerging Markets and ROW contributed 19% and 15% of revenues, respectively, with a focus on local manufacturing and differentiated products.